Nemolizumab (Nemluvio, Galderma) Knocks Out Itch and Burning Across Spectrum of Itchy Disorders
Nemolizumab (Nemluvio, Galderma) is U.S. Food and Drug Administration (FDA) approved to treat atopic dermatitis (AD) and prurigo nodularis (PN), but the interleukin-31 (IL-31) blocker’s anti-pruritic effects may benefit a much larger group of patients with itch. In a case series of patients with more than 20 types of skin diseases associated with pruritus or […]